DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics' stock has experienced significant volatility. Shares rose 86.86% over the past quarter and 60.23% in the last year. Oppenheimer upgraded DMAC's rating to 'outperform' with a target price of $27 per share in January 2026. The company missed its Q3 2025 earnings consensus estimate on November 12, 2025, reporting an EPS of -$0.17. On January 15, 2026, DiaMedica granted options to purchase 50,000 shares to a newly hired non-executive employee. Analyst ratings show a consensus of "Moderate Buy" with an average 1-year price target of $12.33. Technical indicators presented mixed signals, and the stock's closing price on February 6, 2026, was $8.14.

As a clinical-stage biopharmaceutical company, DiaMedica Therapeutics, Inc.'s products are not yet commercialized, so there is no traditional demand seasonality. Demand for its offerings, once commercialized, would likely be driven by medical need and regulatory approvals rather than seasonal factors.

DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company in the Biotechnology industry, focused on developing treatments for ischemic diseases. Their primary product candidate, DM199 (rinvecalinase alfa), is undergoing clinical development for acute ischemic stroke (AIS), preeclampsia (PE), fetal growth restriction, and chronic kidney disease (CKD). The company's pipeline also includes DM300, a preclinical therapy for severe acute pancreatitis.

DiaMedica Therapeutics, Inc. is headquartered in Minneapolis, Minnesota, USA. Its clinical trials, like the ReMEDy2 trial for DM199, are designed to enroll patients globally, reflecting its clinical development reach rather than a commercial geographic footprint.

DiaMedica Therapeutics' brand reputation is mixed but generally leans towards optimism, with a consensus rating of "Moderate Buy". Oppenheimer upgraded its rating to 'outperform' earlier in the year. Weiss Ratings reiterated a "sell" rating in January 2026, and Wall Street Zen downgraded the company from "hold" to "sell" in November 2025. The company provided a business update and announced its full-year 2024 financial results in March 2025. Media coverage has included company updates and changes in personnel.

DiaMedica Therapeutics, Inc. has 135 institutional owners and shareholders, collectively holding 13,812,212 shares. Major institutional shareholders include Cooperman Leon G, BlackRock, Inc., Millennium Management Llc, Paragon Associates & Paragon Associates Ii Joint Venture, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, Vanguard Group Inc, Morgan Stanley, First Manhattan Co, and State Street Corp. Individual insiders hold approximately 47% of the company's shares, with Jan Stahlberg being the largest individual shareholder, owning 16% of outstanding shares.